218 related articles for article (PubMed ID: 25770397)
1. Oncotype DX(®) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence.
You YN; Rustin RB; Sullivan JD
Surg Oncol; 2015 Jun; 24(2):61-6. PubMed ID: 25770397
[TBL] [Abstract][Full Text] [Related]
2. Oncotype DX testing does not affect clinical practice in stage IIa colon cancer.
Allar BG; Messaris E; Poylin VY; Schlechter BL; Cataldo TE
Med Oncol; 2022 Feb; 39(5):59. PubMed ID: 35150339
[TBL] [Abstract][Full Text] [Related]
3. Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients.
Brenner B; Geva R; Rothney M; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Gluzman A; Purim O; Shacham-Shmueli E; Shulman K; Mishaeli M; Man S; Soussan-Gutman L; Tezcan H; Chao C; Shani A; Liebermann N
Value Health; 2016 Jan; 19(1):82-7. PubMed ID: 26797240
[TBL] [Abstract][Full Text] [Related]
4. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.
Srivastava G; Renfro LA; Behrens RJ; Lopatin M; Chao C; Soori GS; Dakhil SR; Mowat RB; Kuebler JP; Kim G; Mazurczak M; Lee M; Alberts SR
Oncologist; 2014 May; 19(5):492-7. PubMed ID: 24710310
[TBL] [Abstract][Full Text] [Related]
5. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.
Clark-Langone KM; Sangli C; Krishnakumar J; Watson D
BMC Cancer; 2010 Dec; 10():691. PubMed ID: 21176237
[TBL] [Abstract][Full Text] [Related]
6. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
[TBL] [Abstract][Full Text] [Related]
7. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.
Hornberger J; Lyman GH; Chien R; Meropol NJ
Value Health; 2012 Dec; 15(8):1014-21. PubMed ID: 23244802
[TBL] [Abstract][Full Text] [Related]
8. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy for stage II colon cancer.
Kopetz S; Freitas D; Calabrich AF; Hoff PM
Oncology (Williston Park); 2008 Mar; 22(3):260-70; discussion 270, 273, 275. PubMed ID: 18494354
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
[TBL] [Abstract][Full Text] [Related]
11. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
13. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
14. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
[TBL] [Abstract][Full Text] [Related]
15. [Adjuvant chemotherapy for colon cancer].
Dahl O
Tidsskr Nor Laegeforen; 2007 Nov; 127(23):3094-6. PubMed ID: 18049502
[TBL] [Abstract][Full Text] [Related]
16. [Adjuvant treatment for resected colon cancer].
Pointet AL; Lepère C; Taieb J
Rev Prat; 2015 Jun; 65(6):789-92. PubMed ID: 26298901
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant systemic chemotherapy for Stage II and III colon cancer after complete resection: an updated practice guideline.
Jonker DJ; Spithoff K; Maroun J;
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):314-22. PubMed ID: 21397476
[TBL] [Abstract][Full Text] [Related]
18. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.
D'Alfonso TM; van Laar RK; Vahdat LT; Hussain W; Flinchum R; Brown N; John LS; Shin SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):705-15. PubMed ID: 23774991
[TBL] [Abstract][Full Text] [Related]
19. Impact of oncotype DX recurrence score in the management of breast cancer cases.
Nguyen MT; Stessin A; Nagar H; D'Alfonso TM; Chen Z; Cigler T; Hayes MK; Shin SJ
Clin Breast Cancer; 2014 Jun; 14(3):182-90. PubMed ID: 24486121
[TBL] [Abstract][Full Text] [Related]
20. New developments in the adjuvant therapy of stage II colon cancer. Risk assessments in the older patient.
McCleary NJ; Meyerhardt JA
Oncology (Williston Park); 2010 Jan; 24(1 Suppl 1):3-8. PubMed ID: 20225605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
